

PATENT

Attorney's Docket No. 05569-0008.PCUS04

13 JAN 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	MONK, Phillip, David et al.
App. No.:	TBA
Conf. No.:	TBA
Int. App. No.:	PCT/GB2004/003059
Int. Filing Date:	July 15, 2004
Title:	HUMAN ANTIBODY MOLECULES FOR IL-13
Art Unit:	TBA
Examiner:	TBA

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail No: EV 439404347 US

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated below and is addressed to MAIL STOP PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

01/13/06
Date

Michael Collins

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. It is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Forms PTO/SB/08A and PTO/SB/08B be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g), this Information Disclosure Statement is not to be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), this Information Disclosure Statement is not to be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

IAP20 Rec'd PCT/PTO 13 JAN 2006

This Information Disclosure Statement does not include copies of cited U.S. patents and U.S. patent publications pursuant to 37 C.F.R. 1.98(a)(2).

This Information Disclosure Statement is being filed prior to the receipt of a first Office Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b)(3).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this document, the Commissioner is hereby authorized to deduct the fees from Howrey Simon Arnold & White, LLP Deposit Account 08-3038, referencing the above-identified attorney docket number.

Respectfully submitted,

HOWREY LLP

Dated: January 13, 2006

By:



Teddy C. Scott, Jr., Ph.D.
Registration No.: 53,573
Customer No.: 22930

HOWREY LLP
321 N. Clark Street, Suite 3400
Chicago, IL 60661
(312) 595-1239 (main)
(312) 846-5621 (direct)
(312) 595-2250 (fax)

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

05569.0008.PCUS04

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	To be assigned 10/564647
Filing Date	Herewith
First Named Inventor	Lutz Jermutus
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	05569.0008.PCUS04

Sheet

1

of

1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Blease, K., et al., "Therapeutic Effect of IL-13 Immunoneutralization During Chronic Experimental Fungal Asthma," The Journal of Immunology, Vol. 166, pp. 5219-5224 (2001)	
	C2	Catalog No. MAB213 - "Monoclonal Anti-human IL-13 Antibody," R & D Systems (October 14, 2002)	
	C3	Catalog No. MAB2131 - "Monoclonal Anti-human IL-13 Antibody," R & D Systems (November 3, 2003)	
	C4	Catalog No. MAB413 - "Monoclonal Anti-mouse IL-13 Antibody," R & D Systems (December 3, 2004)	
	C5	Heinzmann, A., et al., "Genetic Variants of IL-13 Signalling and Human Asthma and Atopy," Human Molecular Genetics, Vol. 9, No. 4, pp. 549-559 (2000)	
	C6	Kuperman, D., et al., "Direct Effects of Interleukin-13 on Epithelial Cells Cause Airway Hyperreactivity and Mucus Overproduction in Asthma," Nature Medicine, Vol. 8, No. 8, pp. 885-889 (2002)	
	C7	Mendez, J., et al., "Functional Transplant of Megabase Human Immunoglobulin Loci Recapitulates Human Antibody Response in Mice," Nature Genetics, Vol. 15, No. 2, pp. 146-156 (1997)	
	C8	PCT International Search Report of PCT/GB2004/003059 dated March 15, 2005	
	C9	Skinninger, B., et al., "Interleukin 13 and Interleukin 13 Receptor are Frequently Expressed by Hodgkin and Reed-Sternberg Cells of Hodgkin Lymphoma," Blood, Vol. 97, No. pp. 250-255 (2001)	
	C10	Wills-Karp, M., et al., "Interleukin-13: Central Mediator of Allergic Asthma," Science, Vol. 282, pp. 2258-2260 (1998)	
	C11	Zhu, Z., et al., "Pulmonary Expression of Interleukin-13 Causes Inflammation, Mucus Hypersecretion, Subepithelial Fibrosis, Physiologic Abnormalities, and Eotaxin Production," Vol. 103, No. 6, pp. 779-788 (1999)	

Examiner
Signature

/Zachary Skelding/

Date

Considered

07/30/2009

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.